Abstract
Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.
| Original language | English |
|---|---|
| Article number | 1449 |
| Journal | Cancers |
| Volume | 11 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2019 |
Fingerprint
Keywords
- Benign prostatic hyperplasia (BPH)
- ELISA
- Exosomes
- Nanoscale flow cytometry
- Prostate cancer (PCa)
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia : A prospective study. / Logozzi, Mariantonia; Angelini, Daniela F.; Giuliani, Alessandro; Mizzoni, Davide; Raimo, Rossella Di; Maggi, Martina; Gentilucci, Alessandro; Marzio, Vittorio; Salciccia, Stefano; Borsellino, Giovanna; Battistini, Luca; Sciarra, Alessandro; Fais, Stefano.
In: Cancers, Vol. 11, No. 10, 1449, 01.10.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia
T2 - A prospective study
AU - Logozzi, Mariantonia
AU - Angelini, Daniela F.
AU - Giuliani, Alessandro
AU - Mizzoni, Davide
AU - Raimo, Rossella Di
AU - Maggi, Martina
AU - Gentilucci, Alessandro
AU - Marzio, Vittorio
AU - Salciccia, Stefano
AU - Borsellino, Giovanna
AU - Battistini, Luca
AU - Sciarra, Alessandro
AU - Fais, Stefano
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.
AB - Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.
KW - Benign prostatic hyperplasia (BPH)
KW - ELISA
KW - Exosomes
KW - Nanoscale flow cytometry
KW - Prostate cancer (PCa)
UR - http://www.scopus.com/inward/record.url?scp=85073472735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073472735&partnerID=8YFLogxK
U2 - 10.3390/cancers11101449
DO - 10.3390/cancers11101449
M3 - Article
AN - SCOPUS:85073472735
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 10
M1 - 1449
ER -